PVLAPalvella Therapeutics Inc
PVLA
Palvella Therapeutics Inc258
Mkt Cap
$1.86BVolume
571,438.0052W High
$151.1852W Low
$20.20PE Ratio
-35.11PVLA Fundamentals
Price
$113.26Prev Close
$130.17Open
$129.0550D MA
$126.62Beta
1.10Avg. Volume
222,471.02EPS (Annual)
-$3.71P/B
57.59Rev/Employee
$0.00$1,138.08
Compact View
Not available
Not available
Poll
Earnings Recap
• Reported GAAP EPS of -$1.20 down -62.16% YoY • Palvella Therapeutics believes its cash and short-term investments of $261.9M as of March 31, 2026, will fund operations for at least twelve months; however, additional capital may be needed thereafter.
Bullish
Palvella Therapeutics achieved positive Phase 3 clinical results for QTORIN rapamycin in microcystic LMs, secured Fast Track Designation for cutaneous VMs, and strengthened its liquidity with a $215.8M equity financing.
Bearish
Palvella Therapeutics reported increased net losses and operating cash burn, faces significant regulatory and manufacturing dependencies, and anticipates future capital raises, risking substantial stockholder dilution.